Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 885-891

  Patel, Himisha ^a   Vogl, Dan T ^a   Aqui, Nicole ^a   Shaked, Abraham ^a   Olthoff, Kim ^a   Markmann, James ^a   Reddy, Rajender ^a   Stadtmauer, Edward A ^a   Schuster, Stephen ^a   Tsai, Donald E ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Epstein Barr virus; Liver transplantation; Lymphoproliferative disorder; Posttransplant lymphoma; PTLD

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; RECURRENCE; TREATMENT OUTCOME; VINCRISTINE;

EID: 34547420053     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701223275     Document Type: Article

References (27)

1. Penn, I. (1990) Cancers complicating organ transplantation. N Engl J Med, 323, pp. 1767-1769.
2. Gostsschalk, S., Rooney, C. and Heslop, H. E. (2005) Posttransplant lymphoproliferative disorders. Annu Rev Med, 56, pp. 29-44.
3. Morrison, V. A., Dunn, D. L., Manivel, J. C., Gajl-Peczalska, K. J. and Peterson, B. A. (1994) Clinical characteristics of posttransplant lymphoproliferative disorders. Am J Med, 97, pp. 14-24.
4. Penn, I. (1992) Immunosuppression - a contributory factor in lymphoma formation. Clin Transplant, 6, p. 214.
5. Starzl, T. E., Nalesnik, M. A., Porter, K. A., Iwatsuki, S. and Griffith, B. P. (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet, 1, pp. 583-587.
6. Tsai, D. E., Hardy, C., Somer, B. G., Oltoff, K. M., Kotloff, R. M. and Tomaszewski, J. E. (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder (PTLD): Analysis of prognostic variables and long term follow-up of 42 patients. Transplantation, pp. 1076-1088.
7. Dotti, G., Fiocchi, R., Motta, T., Mammana, C., Gotti, E. and Riva, S. (2002) Lymphoma occuring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation, 74, pp. 1095-1102.
8. Mamzer-Bruneel, M. -F., Lome, C., Morelon, E., Levy, V., Bourquelot, P. and Jacobs, F. (2000) Durable remission after aggressive chemotherapy for very late post-kidney transplant proliferation: A report of 16 cases observed in a single center. J Clin Oncol, 18, pp. 3622-3632.
9. Swinnen, L. J., Mullen, G. M., Carr, T. J., Costanzo, M. R. and Fisher, R. I. (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood, 86, pp. 3333-3340.
10. Elstrom, R. L., Andreadis, C., Aqui, N. A., Ahya, V. N., Bloom, R. D. and Brozena, S. C. (2006) Treatment of PTLD with rituximab or chemotherapy. Am J Transplant, 6, pp. 569-576.
11. Benkerrou, M., Jais, J., Leblond, V., Durandy, A., Sutton, L. and Bordigoni, P. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long term outcome. Blood, 92, pp. 3137-3147.
12. Berney, T., Delias, S., Kato, T., Nishida, S., Mittal, N. K. and Madariaga, J. (2002) Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation, 74, pp. 1000-1006.
13. Faye, A., Quartier, P., Reguerre, Y., Lutz, P., Carret, A. S. and Dehee, A. (2001) Chimaeric anti-CD20 monoclonal antibody (rituximab) in posttransplant lymphoproliferative disorder following stem cell transplantation in children. Br J Haemotol, 115, pp. 112-118.
14. Fischer, A., Blanche, S., Bidois, J Le, Bordigoni, P., Garnier, J. L. and Niaudet, P. (1991) Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med, 324, pp. 1451-1456.
15. Montone, K. T., Litzky, L. A., Wurster, A., Kaiser, L., Palevsky, H Bavaria, Pietra, G. G. and Tomaszewski, J. E. (1996) Analysis of Eptein-Barr virus related localized hepatic lymphoproliferative disorders after liver transplantation. Cancer, 76, p. 1344.
16. Chen, J. M., Barr, M. L. and Chadburn, A. (1993) Management of lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transplant, 6, pp. 570-574.
17. Finn, L., Reyes, J., Bueno, J. and Yunis, E. (1998) Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol, 22, pp. 299-309.
18. Mihalov, M. L., Gattuso, P., Abraham, K., Holmes, E. W. and Reddy, V. (1996) Incidence of posttransplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant, 10, pp. 248-255.
19. Hanto, D. W., Frizzera, G., Gajl-Peczalska, K. J. and Simmons, R. L. (1985) Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation, 39, pp. 461-472.
20. Boubenider, S., Hiesse, C., Goupe, C., Kriaa, F., Merchand, S. and Charpentier, B. (1997) Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol, 10, pp. 136-145.
21. Nalesnik, M. A. (2001) The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transplant Infect Dis, 3, pp. 88-96.
22. Kogan-Liberman, D., Burroughs, M., Emre, S., Moscona, A. and Shneider, B. L. (2001) The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: A preliminary experience. J Ped Gastroenterol, 33, pp. 445-449.
23. Lee, T. C., Savoldo, B., Barshes, N. R., Rooney, C. M., Heslop, H. E., Gee, A. P., Caldwell, Y., Scott, J. D. and Goss, J. A. (2006) Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant, 20, pp. 389-393.
24. Choquet, S., Leblond, V., Herbrecht, R., Socie, G., Stoppa, A. M. and Vandenberghe, P. (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative diosrders: Results of a prospective multicenter phase 2 study. Blood, 107, pp. 3053-3057.
25. Garrett, T. J., Chadburn, A., Barr, M. L., Drusin, R. E., Chen, J. M. and Schulman, L. L. (1993) Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin- vincristine-prednisone chemotherapy. Cancer, 72, pp. 2782-2785.
26. Newell, K. A., Millis, J., Bruce, D. S., Woodle, E. S., Cronin, D. C. and Loss, G. (1998) An analysis of hepatic retransplantation in children. Transplantation, 65, pp. 1172-1178.
27. Rappaport, D. C., Hanbidge, A., Merchant, N., Shepherd, F. A. and Greig, P. D. (2001) Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging, 26, pp. 200-206.